Syros Pharmaceuticals – pharmaceutical daily

December 8, 2020 Off

Syros Closes $90.5 Million Strategic Financing

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today…

October 24, 2019 Off

Syros data from Phase 2 Trial of SY-1425 plus Azacitidine shows benefits in RARA-positive newly diagnosed unfit AML patients

By BusinessWire

Syros’s SY-1425 plus Azacitidine testing data showed 62% composite complete response rate, with 82% of patients achieving or maintaining transfusion…

April 9, 2019 Off

Syros Announces Closing of Concurrent Public Offerings

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today…

April 5, 2019 Off

Syros Announces Pricing of $70 Million Concurrent Public Offerings

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today…

April 5, 2019 Off

Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today…